

22-24 September, 2025 AstraZeneca, Mölndal, Sweden

The 8th International Symposium on **Solid Oral Dosage Forms**

Preliminary program

Monday, 22 September

16.00 – 16.30 Registration & Poster mounting

16.30 – 16.40 Opening of the conference

Chair: Name

16.40 – 17.20 Plenary lecture: Powder compression and compaction – assessment and prediction Göran Alderborn, Uppsala University, Sweden

17.20 – 17.50 **GaBi Award: Oral delivery of macromolecules formulated with permeation enhancers**Staffan Berg, AstraZeneca, Sweden

17.50 – 19.30 Poster Session and Exhibition with Welcome Mingle (food and drinks)

Tuesday, 23 September

08.00 - 8.45 Registration & Poster mounting

08.45 – 8.55 Welcome

SESSION 1: Manufacturing

Chair: Name

08.55 – 9.40 Plenary lecture: Sustainability and life cycle analysis

George Grimsey Jones, Croda International, UK

09.40 – 10.05 Artificial intelligence and machine learning in tablet manufacturing

Anne Juppo, University of Helsinki, Finland

10.05 – 10.35 Coffee, Posters & Exhibition

10.35 – 11.00	Selection of excipients to design Continuous Manufacturing Processes Pirjo Tajarobi, AstraZeneca, Sweden
11.00 – 11.25	Technology transfer from batch to continuous manufacturing Ossi Korhonen, University of Eastern Finland, Finland
11.25 – 11.50	Solid-state characterisation to guide formulation optimisation Martin Lindsjö, Magle Chemoswed, Sweden
11.50 – 13.00	Lunch
SESSION 2: P	rediction and advanced characterization
Chair: Name 13.00 – 13.45	Plenary lecture: 'Al and simulation – a new era for accelerated pharmaceutical development' Gavin Reynolds, AstraZeneca, UK
13.45 – 14.10	Digital process design – digital twin/PBPK model software Guillermo Jimeno, Siemens, UK
14.10 – 14.40	Accelerated development of complex oral solid dosage forms: impact of process parameters of quality attributes Friedrike Guetter, Korsch AG, Berlin
14.40 – 15.05	Coffee, Posters & Exhibition
15.05 – 15.30	Modelling powder compression and compaction – nonlocal elastoplastic-adhesive contact model Göran Frenning, Uppsala University, Sweden
15.30 – 15.55	Insights to solid formulations – analytical tools for the mico-scale structural analysis Denny Mahlin, RISE, Sweden
15.55 – 16.20	From material to product Performance: digital-driven formulation design Daniel Markl, University of Strathclyde, UK
16.20 – 16.45	Cracking the code for oral amorphous drugs Staffan Schantz, AstraZeneca, Sweden
17.30 – 18.30	Posters, Exhibition & drinks
19.00	Symposium Dinner

Wednesday, 24 September

08.30 – 8.45 Welcome

SESSION	_	er and a second	and the second second
SESSION	3:	Further dev	velopments

_						
	hai	i r	N	_	m	$\overline{}$
١.	па		1.	М		н

Chair: Name	
08.45 – 9.30	Plenary lecture: Regulatory aspects of excipients Lotte Kok, Novo Nordisk, Denmark and IPEC Europe
09.30 – 9.55	PHARMECO advancing SSbD practices in pharmaceutical manufacturing Nicolaas Schipper, RISE, Sweden
09.55 – 10.25	Coffee, Posters & Exhibition
10.25 – 10.50	Porous algae cellulose for stable amorphous solid dispersions Albert Mihranyan, Veltio Pharma and Uppsala University, Sweden
10.50 – 11.15	Accelerating use of new excipient suppliers Iain Moore, EXCiPACT, BE
11.15 – 11.30	Presentation selected from abstracts
11.30 – 12.00	Title to be confirmed Ardena, Gent, BE
12.00 – 13.15	Lunch
SESSION 4: N	ew developments
13.15 – 14.00	Plenary lecture: understanding formulation development better through machine
	learning analysis René Holm, University of Southern Denmark, Denmark
14.00 – 14.25	learning analysis
	learning analysis René Holm, University of Southern Denmark, Denmark Fully amorphous hybrid nanoparticles with enhanced clinical properties − scaling hyNap™ to GMP and regulatory approval
14.25 – 15.00	learning analysis René Holm, University of Southern Denmark, Denmark Fully amorphous hybrid nanoparticles with enhanced clinical properties − scaling hyNap™ to GMP and regulatory approval Per Andersson, XSpray, Sweden
14.25 – 15.00 15.00 – 15.15	learning analysis René Holm, University of Southern Denmark, Denmark Fully amorphous hybrid nanoparticles with enhanced clinical properties − scaling hyNap™ to GMP and regulatory approval Per Andersson, XSpray, Sweden Coffee, Posters & Exhibition

Sponsors



